These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 18574651)
41. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis. Hamada Y; Seto Y; Yago K; Kuroyama M J Infect Chemother; 2012 Aug; 18(4):501-7. PubMed ID: 22231601 [TBL] [Abstract][Full Text] [Related]
42. Utilisation, efficacy and safety of voriconazole: prospective, non-interventional study on treatment of IFIs in clinical practice. Heinz WJ; Silling G; Böhme A Curr Med Res Opin; 2011 Feb; 27(2):335-42. PubMed ID: 21155707 [TBL] [Abstract][Full Text] [Related]
43. Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate. van Hasselt JG; van Eijkelenburg NK; Huitema AD; Schellens JH; Schouten-van Meeteren AY Antimicrob Agents Chemother; 2013 Jun; 57(6):2878-81. PubMed ID: 23571545 [TBL] [Abstract][Full Text] [Related]
44. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients. Imataki O; Yamaguchi K; Uemura M; Fukuoka N Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914 [TBL] [Abstract][Full Text] [Related]
45. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Purkins L; Wood N; Greenhalgh K; Allen MJ; Oliver SD Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):10-6. PubMed ID: 14616408 [TBL] [Abstract][Full Text] [Related]
46. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia. Przepiorka D; Buadi FK; McClune B Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475 [TBL] [Abstract][Full Text] [Related]
51. [Diagnosis and treatment of pulmonary aspergillosis. Role of voriconazole (discussion)]. Kohno S; Ogawa K; Kurashima A; Niki Y; Maesaki S Jpn J Antibiot; 2007 Dec; 60(6):321-34. PubMed ID: 18447204 [No Abstract] [Full Text] [Related]
52. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570 [TBL] [Abstract][Full Text] [Related]
53. A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections. Yilmaz D; Balkan C; Ay Y; Akin M; Karapinar B; Kavakli K Mycoses; 2011 May; 54(3):234-42. PubMed ID: 19906090 [TBL] [Abstract][Full Text] [Related]
54. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Zeuli JD; Wilson JW; Estes LL Antimicrob Agents Chemother; 2013 Mar; 57(3):1121-7. PubMed ID: 23229485 [TBL] [Abstract][Full Text] [Related]
55. The treatment of pulmonary Wangiella dermatitidis infection with oral voriconazole. Bulloch MN J Clin Pharm Ther; 2011 Jun; 36(3):433-6. PubMed ID: 21062332 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Andrews E; Damle BD; Fang A; Foster G; Crownover P; LaBadie R; Glue P Br J Clin Pharmacol; 2008 Apr; 65(4):531-9. PubMed ID: 18294327 [TBL] [Abstract][Full Text] [Related]